Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.5M Buy
9,675
+123
+1% +$42.1K 1.93% 17
2026
Q1
$3.36M Sell
9,552
-234
-2% -$83.4K 2.21% 16
2025
Q4
$3.2M Sell
9,786
-417
-4% -$132K 2.59% 13
2025
Q3
$2.88M Buy
10,203
+657
+7% +$191K 2.33% 25
2025
Q2
$2.67M Sell
9,546
-56
-0.6% -$15.9K 2.68% 18
2025
Q1
$2.99M Buy
9,602
+484
+5% +$143K 2.7% 9
2024
Q4
$2.38M Buy
+9,118
New +$2.71M 2.03% 25

Other funds holding AMGN

Integras Partners's AMGN Position: Q2 2026 in Review

Integras Partners increased its Amgen (AMGN) stake by 1.3% in Q2 2026, buying an estimated $42.1K and bringing the position to 9,675 shares worth $3.5M. The position accounts for 1.93% of the portfolio, ranked #17.

Integras Partners first reported a position in AMGN in Q4 2024 and has held it in 7 quarters since. 1,540 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Integras Partners held 9,675 shares of Amgen worth $3.5M as of Q2 2026.
  • Integras Partners bought 123 Amgen shares in Q2 2026, an estimated $42.1K.
  • Amgen made up 1.93% of Integras Partners's portfolio in Q2 2026, its #17 holding.
  • Integras Partners first reported a position in Amgen in Q4 2024 and has held it in 7 quarters since.
  • 1,540 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Integras Partners's 13F filing for Q2 2026, filed 24 Jul 2026.